Boston Immune Technologies and Therapeutics Raises $10M Series A Financing

19 Mar, 2021

Boston Immune Technologies and Therapeutics Raises $10M Series A Financing
Photo by Dimitry Anikin on Unsplash

– Boston Immune Technologies and Therapeutics, Inc. (BITT) is a Boston, MA based developer of novel TNF Superfamily antagonist antibodies.
– Company raised $10M Series A/A1 financing.
– Investors included BeiGene, Ltd., along with undisclosed private investors and prior investors Hatteras Venture Partners and EGP Investments.
– The company intends to use the funds for the clinical development of BIR2101, a novel, TNFR2 antagonist antibody for indications in oncology and infectious disease and additional pipeline candidates.

Biotechnology North America Therapeutics
Crunchbase icon

Content report

The following text will be sent to our editors: